Methodologies in Biosimilar Product Development Methodologies in Biosimilar Product Development
Chapman & Hall/CRC Biostatistics Series

Methodologies in Biosimilar Product Development

    • $59.99
    • $59.99

Publisher Description

Methodologies for Biosimilar Product Development covers the practical and challenging issues that are commonly encountered during the development, review, and approval of a proposed biosimilar product. These practical and challenging issues include, but are not limited to the mix-up use of interval hypotheses testing (i.e., the use of TOST) and confidence interval approach, a risk/benefit assessment for non-inferiority/similarity margin, PK/PD bridging studies with multiple references, the detection of possible reference product change over time, design and analysis of biosimilar switching studies, the assessment of sensitivity index for assessment of extrapolation across indications without collecting data from those indications not under study, and the feasibility and validation of non-medical switch post-approval.

Key Features:
Reviews withdrawn draft guidance on analytical similarity assessment. Evaluates various methods for analytical similarity evaluation based on FDA’s current guidelines. Provides a general approach for the use of n-of-1 trial design for assessment of interchangeability. Discusses the feasibility and validity of the non-medical switch studies. Provides innovative thinking for detection of possible reference product change over time.
This book embraces innovative thinking of design and analysis for biosimilar studies, which are required for review and approval of biosimilar regulatory submissions.

GENRE
Science & Nature
RELEASED
2021
September 30
LANGUAGE
EN
English
LENGTH
392
Pages
PUBLISHER
CRC Press
SELLER
Taylor & Francis Group
SIZE
11.6
MB
Statistical Issues in Drug Research and Development Statistical Issues in Drug Research and Development
2017
State of the Art Instead of Biological Variation to Set Requirements for Imprecision (Letters) (Letter to the Editor) State of the Art Instead of Biological Variation to Set Requirements for Imprecision (Letters) (Letter to the Editor)
2000
When to Collect Blood Specimens: Midmorning vs Fasting Samples (Laboratory and Management) When to Collect Blood Specimens: Midmorning vs Fasting Samples (Laboratory and Management)
1998
The Role of the Study Director in Nonclinical Studies The Role of the Study Director in Nonclinical Studies
2014
Advances in Artificial Intelligence, Computation, and Data Science Advances in Artificial Intelligence, Computation, and Data Science
2021
Metabolomics Metabolomics
2019
Medical Risk Prediction Models Medical Risk Prediction Models
2021
Real-World Evidence in Drug Development and Evaluation Real-World Evidence in Drug Development and Evaluation
2021
Biomarker Analysis in Clinical Trials with R Biomarker Analysis in Clinical Trials with R
2020
Biosimilar Clinical Development: Scientific Considerations and New Methodologies Biosimilar Clinical Development: Scientific Considerations and New Methodologies
2016
Innovative Methods for Rare Disease Drug Development Innovative Methods for Rare Disease Drug Development
2020
Statistical Design, Monitoring, and Analysis of Clinical Trials Statistical Design, Monitoring, and Analysis of Clinical Trials
2021